A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

Summary

The primary purpose of this study is to evaluate the efficacy of the study drug known as LY2875358, administered alone or in combination with a second drug named Erlotinib, in participants affected by a defined type of lung cancer (MET biomarker diagnostic positive Non-Small-Cell Lung Cancer) that experienced a disease progression during the most recent treatment with Erlotinib.

Timeline

Start

2013-08

Primary completion

2015-02

Completion

2016-03

Drugs

Indications